The current status of targeting BAFF/BLyS for autoimmune diseases

Table 1 List of current and potential BAFF antagonists

	Blocks BAFF
Therapeutic agent	Soluble	Membrane	Blocks APRIL	Current status	Reference
LymphoStat-B (Human Genome Sciences)	+	-	-	Phase II clinical trials^a	[38]
BAFF-R-Ig (Biogen Idec)	+	+	-	In development	[39]
TACI-Ig (ZymoGenetics Serono)	+	+	+	Phase I clinical trials	[28]
BCMA-Ig	+^b	+/-	+	-	[39]
Mutated BCMA-Ig	-	-	+	-	[40]
MiniBR3 (BAFF-R)	+	+	-	Pre-clinical	[37]
Peptidomimetics of:
BAFF-R	+	+	-	Pre-clinical	[37]
TACI	+	+	+	Hypothetical	[37]
BCMA	+	+	+	Hypothetical	[37]

^aSystemic lupus erythematosus and rheumatoid arthritis. ^bLow affinity for BAFF. BAFF-R, BAFF receptor; BCMA, B cell maturation antigen; TACI, transmembrane activator and calcium modulator ligand interactor.

ISSN: 1478-6362